Targeting Metastasis at the Root: Precision Therapy and Companion Diagnostics - EIC Pathfinder Planning

Important results from the project

We required Vinnova’s support to prepare a competitive EIC Pathfinder Open 2026 application. The funding was used to structure the project plan, establish the consortium with Lund University, Erasmus University, and the Institute of Cancer Research, and define partners’ roles. Efforts focused on refining the scientific roadmap and socioeconomic impact to meet rigorous requirements. The goal is a novel antibody that inhibits tumour growth and metastasis without affecting normal components.

Expected long term effects

EIC funding will drive a science-to-technology breakthrough, transitioning our innovation from laboratory concept to a validated preclinical stage. The project will help confirm proof of concept, establishing a first-in-class cancer treatment with a superior safety profile. By integrating companion diagnostics we enable a prophylactic treatment. This proactive intervention offers economic benefits and better patient life by a disruptive, gender-independent solution for aggressive malignancies.

Approach and implementation

Through internal efforts and external expertise, the project plan was structured and a consortium established. Key actions included defining partners’ and their roles, refining the scientific and technological roadmap, and situating the initiative within a socioeconomic impact to meet formal requirements. All tasks were completed as planned, preparation of a competitive proposal was carried out to finish the submission on time.